Shares of Enzo Biochem have been flying over the past year due to increased demand for its clinical products, successful patent resolutions and new product introductions, says the company's president Barry Weiner. Enzo recently pocketed a multi-million dollar settlement from Affymetrix and Weiner expects the successful legal resolutions to continue without disrupting the ongoing business. Weiner also says the harsh winter weather hurt Enzo's clinical business in the first quarter as fewer patients braved the cold to go to the doctor, yet he expects that to normalize going forward.

If you liked this article you might like

Disney, Nvidia, Walmart and 12 Other Stocks That Could Skyrocket Going Into 2018

These Undervalued Stocks Are Unfairly Overlooked

Analysts' Actions -- CVS Health, Micron, Qualcomm, Pandora and More

4 Health Care Stocks Under $10 to Watch